SCHOTT Pharma India Renames, Keeps 3B+ Annual Containers
On 28 October 2026, SCHOTT Poonawalla Private Limited announced that it will become SCHOTT Pharma India Private Limited, a change that aligns the Indian business more closely with the global SCHOTT Pharma network. The press release emphasizes that the name change does not affect ownership, management, employees, business strategy, operations, product portfolio, services, or existing customer commitments.
The company highlights its heritage of more than 140 years in glass technology and its role as India’s sole manufacturer of glass pre‑fillable syringes and sterile formats. It produces over 3 billion containers per year, a capacity that translates to approximately 7,000 injections delivered to patients each minute worldwide.
During the COVID‑19 pandemic, SCHOTT Pharma India’s pharmaceutical vials were used for more than 4.3 billion vaccine doses globally, including 3 billion doses administered in India. This underscores the firm’s contribution to the pandemic response.
Looking forward, SCHOTT Pharma India plans significant investments to expand manufacturing capacity for pre‑fillable syringes and cartridges. These expansions are intended to support the growing demand for biologics, biosimilars, GLP‑1‑based treatments, and other advanced injectable therapies.
Roy Joseph, CEO & Managing Director of SCHOTT Pharma India, stated that the new identity combines the company’s Indian strength with SCHOTT Pharma’s global innovation, and that the focus will remain on growing with customers and ensuring safe delivery of critical therapies. Dr. Christian Mias, CEO of SCHOTT Pharma AG & Co. KGaA and major shareholder, reiterated that the name change reinforces the strategic partnership and confirms long‑term commitment to India as a key pharmaceutical hub.
The release, distributed by Business Wire India from Mumbai, Maharashtra, reiterates the company’s commitment to innovation, quality, scientific excellence, and sustainability while supporting India’s expanding role in the global pharmaceutical value chain.